FRANKFURT, Feb 3 (Reuters) - Britain's GlaxoSmithKline
and German biotech firm CureVac struck a deal
to develop next-generation vaccines against COVID-19 that target
several variants in one product.
In a joint statement on Wednesday, the partners said they
were targeting a possible launch in 2022.
GSK will also support the production of up to 100 million
doses of CureVac's first generation COVID-19 vaccine candidate
in 2021, they said.
(Reporting by Ludwig Burger; editing by Thomas Seythal)